Alignment Stock Surges After 2.48% Medicare Rate Hike

The U.S. government confirmed it will raise 2027 Medicare Advantage and Part D payments by an average of 2.48%, according to Reuters. CMS officials said insurers will also receive an additional 2.5% uplift tied to adjustments in risk-scoring formulas, bringing the effective increase to roughly 5%. CMS estimates the final rule will push more than $13 billion in extra funding into Medicare Advantage plans.

From draft to final: payments revised after market reaction

The final figure represents a turnaround from the January draft, which proposed essentially flat reimbursement and triggered a sector-wide selloff.

Insurers view the change as a win

Insurers are framing the move as a positive outcome after the shift from 0.09% to 2.48%, plus the added 2.5% tied to risk adjustment. Morningstar’s Julie Utterback said the final rule provides carriers with a more realistic framework for modeling 2027 medical expenses.

Kevin Gade of Bahl and Gaynor estimated that, once all methodology tweaks are included, the real-world increase may land closer to 3.5%–4%. He characterized the result as “a win.”

CMS delays some risk-model changes to reduce disruption

Regulators also decided to delay certain risk-model changes that insurers said could be destabilizing if implemented too quickly. CMS acknowledged that some carriers had already begun dropping capitated plans—arrangements that pay a fixed amount per member—and that some providers had exited Medicare Advantage networks.

Alignment stock: technical picture and key levels

At $22.12, Alignment shares were trading 25.7% above their 20-day simple moving average (SMA), suggesting short-term trend control has shifted back to buyers. The stock was also 13.9% above its 100-day SMA, indicating the intermediate trend remains upward despite recent volatility.

Moving average convergence divergence (MACD) was described as bullish, with the MACD at -0.3547 above the signal line at -0.6062, suggesting downside pressure has been fading. However, the 20-day SMA remains below the 50-day SMA, indicating the shorter-term trend improvement is relatively recent.

Key resistance: $23.50, where rallies have recently stalled.
Key support: $20.00, an area where buyers have tended to step in.

Analyst consensus and recent rating actions

Alignment carries a Buy rating with an average price target of $19.22. Recent analyst moves cited in the article include:

• JP Morgan: Overweight (raises target to $26.00) (Feb. 5)
• TD Cowen: Buy (raises target to $25.00) (Jan. 16)
• UBS: Neutral (raises target to $21.00) (Jan. 14)

Benzinga Edge: momentum improving, value weak

The Benzinga Edge scorecard highlighted a Momentum score of 32.78 (neutral), indicating the trend is improving but not yet a broad market leader. The Value score was 7.05 (weak), suggesting the stock screens poorly on value metrics versus peers.

The article characterized the combination as consistent with a “pay for growth/turnaround” profile, where execution and upcoming catalysts may matter more than cheapness.

Price action at publication

According to Benzinga Pro, Alignment shares were up 19.44% at $22.30 at the time of publication on Tuesday.